A detailed history of Nantahala Capital Management, LLC transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Nantahala Capital Management, LLC holds 1,270,035 shares of AURA stock, worth $11.1 Million. This represents 0.67% of its overall portfolio holdings.

Number of Shares
1,270,035
Previous 1,270,035 -0.0%
Holding current value
$11.1 Million
Previous $9.6 Million 17.86%
% of portfolio
0.67%
Previous 0.64%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$6.81 - $7.89 $352,928 - $408,899
-51,825 Reduced 3.92%
1,270,035 $9.6 Million
Q4 2023

Feb 14, 2024

BUY
$7.02 - $11.98 $4.06 Million - $6.92 Million
577,968 Added 77.7%
1,321,860 $11.7 Million
Q3 2023

Nov 14, 2023

SELL
$8.97 - $12.38 $533,114 - $735,780
-59,433 Reduced 7.4%
743,892 $6.67 Million
Q2 2023

Aug 14, 2023

SELL
$8.51 - $13.33 $341,429 - $534,812
-40,121 Reduced 4.76%
803,325 $9.92 Million
Q1 2023

May 15, 2023

BUY
$8.88 - $12.11 $396,891 - $541,256
44,695 Added 5.6%
843,446 $7.83 Million
Q4 2022

Feb 14, 2023

BUY
$9.86 - $14.59 $4.09 Million - $6.05 Million
414,987 Added 108.14%
798,751 $8.39 Million
Q3 2022

Nov 10, 2022

BUY
$13.1 - $20.34 $531,191 - $824,766
40,549 Added 11.81%
383,764 $6.95 Million
Q2 2022

Aug 15, 2022

BUY
$12.37 - $21.86 $509,953 - $901,178
41,225 Added 13.65%
343,215 $4.86 Million
Q1 2022

May 13, 2022

BUY
$15.94 - $23.34 $3.23 Million - $4.73 Million
202,844 Added 204.59%
301,990 $6.64 Million
Q4 2021

Feb 14, 2022

BUY
$14.76 - $24.89 $1.46 Million - $2.47 Million
99,146 New
99,146 $1.68 Million

Others Institutions Holding AURA

About Aura Biosciences, Inc.


  • Ticker AURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,273,600
  • Market Cap $256M
  • Description
  • Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...
More about AURA
Track This Portfolio

Track Nantahala Capital Management, LLC Portfolio

Follow Nantahala Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.